PACB Q3 2026 deep dive: clinical adoption and AI partnerships drive steady growth
Genomics company Pacific Biosciences of California (NASDAQ:PACB) announced better-than-expected revenue in Q3 2026, with sales up 5.5% year on year to $40.56 million. Its non-GAAP loss of $0.11 per share was 16.1% above analysts’ consensus estimates. Is now the time to buy PACB? Find out…